TY - JOUR
T1 - Size of the nanovectors determines the transplacental passage in pregnancy
T2 - Study in rats
AU - Refuerzo, Jerrie S.
AU - Godin, Biana
AU - Bishop, Karen
AU - Srinivasan, Srimeenakshi
AU - Shah, Shinil K.
AU - Amra, Sarah
AU - Ramin, Susan M.
AU - Ferrari, Mauro
N1 - Funding Information:
This study was supported in part by the Center for Clinical and Translational Sciences, which is funded by National Institutes of Health Clinical and Translational Award UL1 RR024148 (TL1 RR024147 for the T32 program; KL2 RR0224149 for the K12 program) from the National Center for Research Resources.
PY - 2011/6
Y1 - 2011/6
N2 - Objective: The objective of the study was to examine whether the size of silicon nanovectors (SNVs) inhibits their entrance into the fetal circulation. Study Design: Pregnant rats were intravenously administered with SNVs or saline. The SNVs were spherical particles with 3 escalating diameters: 519 nm, 834 nm, and 1000 nm. The maternal and fetal distribution of SNVs was assessed. Results: In animals that received 1000 or 834 nm SNV, silicon (Si) levels were significantly higher in the maternal organs vs the saline group, whereas the silicon levels in fetal tissues were similar to controls. However, in animals receiving 519 nm SNVs, fetal silicon levels were significantly higher in the SNV group compared with the saline group (5.93 ± 0.67 μg Si per organ vs 4.80 ± 0.33, P = .01). Conclusion: Larger SNVs do not cross the placenta to the fetus and, remaining within the maternal circulation, can serve as carriers for harmful medications in order to prevent fetal exposure.
AB - Objective: The objective of the study was to examine whether the size of silicon nanovectors (SNVs) inhibits their entrance into the fetal circulation. Study Design: Pregnant rats were intravenously administered with SNVs or saline. The SNVs were spherical particles with 3 escalating diameters: 519 nm, 834 nm, and 1000 nm. The maternal and fetal distribution of SNVs was assessed. Results: In animals that received 1000 or 834 nm SNV, silicon (Si) levels were significantly higher in the maternal organs vs the saline group, whereas the silicon levels in fetal tissues were similar to controls. However, in animals receiving 519 nm SNVs, fetal silicon levels were significantly higher in the SNV group compared with the saline group (5.93 ± 0.67 μg Si per organ vs 4.80 ± 0.33, P = .01). Conclusion: Larger SNVs do not cross the placenta to the fetus and, remaining within the maternal circulation, can serve as carriers for harmful medications in order to prevent fetal exposure.
KW - medications
KW - silicon nanovector
KW - transplacental passage
UR - http://www.scopus.com/inward/record.url?scp=79958099232&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=79958099232&partnerID=8YFLogxK
U2 - 10.1016/j.ajog.2011.02.033
DO - 10.1016/j.ajog.2011.02.033
M3 - Article
C2 - 21481834
AN - SCOPUS:79958099232
SN - 0002-9378
VL - 204
SP - 546.e5-546.e9
JO - American Journal of Obstetrics and Gynecology
JF - American Journal of Obstetrics and Gynecology
IS - 6
ER -